Superworth

Seres Therapeutics profit margin MCRB

Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.

Net margin, 12 months
n/m
not a meaningful number
Peer median
9.2%

Seres Therapeutics' net margin works out at −1193% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025n/an/a
FY2024n/an/a
FY2023−90.0%−83.2%
FY2022n/an/a
FY2021−45.2%−44.5%
FY2020n/an/a
FY2019n/an/a
FY2018n/an/a
FY2017n/an/a
FY2016n/an/a
FY2015n/an/a
FY2014n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25n/an/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24−65.2%n/a−54.4%
Q4 FY23−90.0%n/a−83.2%
Q3 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Seres Therapeutics' size, closest first, today.

CompanyProfit margin
MCRBSeres Therapeuticsn/m
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeutics15.7%
LFVNLifevantage2.8%
Peer median9.2%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Seres Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.